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OBJECTIVES We evaluated the association of mode of brain death with cardiac allograft vasculopathy.
BACKGROUND Explosive brain death (EBD) is accompanied by a sudden increase in intracranial pressure,
with recruitment of pro-inflammatory cytokines, as well as adhesion cell and co-stimulatory
molecules. Whether these early events influence the later development of cardiac allograft
vasculopathy following heart transplantation remains unknown.
METHODS An inception cohort of 61 consecutive heart transplant recipients between 1993 and 1995
who underwent intravascular ultrasound examination of the coronary arteries were evaluated.
Based on the mode of donor brain death, this cohort was divided into either an EBD group
(n 27) or non-EBD (n  34), and the development of intimal thickness and cardiac events
(sudden cardiac death, myocardial infarction, and need for coronary revascularization via
percutaneous techniques or surgical bypass) was assessed.
RESULTS Despite similar posttransplant survival and distribution of nonimmunological and immuno-
logical variables, heart transplant recipients with EBD demonstrated greater intimal thick-
ening (0.59  0.1 vs. 0.32  0.2 mm; p  0.02) and higher cardiac events (37% vs. 12%; p
 0.01) when compared to those with non-EBD donors. Hearts from donors with EBD had
lower survival (63  19 vs. 72  17 months) than with non-EBD donors (p  0.04).
CONCLUSIONS Explosive brain death is a significant determinant for the late development of cardiac allograft
vasculopathy and influences long-term allograft survival. Thus, strategies focusing on
limitation of vascular allograft injury in the pre-engraftment phase of cardiac transplantation
are warranted. (J Am Coll Cardiol 2004;43:806–10) © 2004 by the American College of
Cardiology FoundationT
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hnvestigations in experimental models of brain death and in
otential donors for cardiac transplantation have demon-
trated that brain death is associated with pathological
ffects on the myocardium that adversely influence cardiac
erformance (1). Indeed, some investigators have postulated
hat the process of brain death is accompanied by inflam-
atory processes that contribute to diffuse endothelial
ysfunction and that this sentinel event may adversely
nfluence the outcome of engraftment (2). Other animal
tudies have pointed to the fact that the pathological
onsequences as a result of mode of brain death might
dversely influence cardiac function. Shivalkar and col-
eagues (3) have demonstrated in canine experiments that
ogs with a nonexplosive rise in intracranial pressure
howed fewer cardiac hemodynamic perturbations and less
yocardial injury than did those animals subjected to a
apid and more explosive rise in intracranial pressures.
Cardiac allograft vasculopathy is associated with a relent-
ess course after heart transplantation, and both non-
mmunological and immunological interventions have only
artially modified its natural history (4,5). Recent investi-
ations have alluded to early posttransplant rejection-
ndependent microvascular aberrations that predict the late
evelopment of posttransplant coronary artery disease (6,7).
From the Ochsner Cardiomyopathy and Heart Transplantation Center, Ochsner
edical Institutions, New Orleans, Louisiana.uManuscript received July 25, 2003; accepted August 13, 2003.he purpose of our investigation was to evaluate the
elationship of mode of donor brain death with incidence
nd severity of cardiac allograft vasculopathy in heart trans-
lantation.
ETHODS
atient population. The study population consisted of a
ohort of 61 consecutive heart transplant recipients between
993 and 1995 who underwent examination of the coronary
rteries using intravascular ultrasound. These patients were
ivided by mode of donor brain death into either group I:
on-explosive brain death (EBD) (n  34), or group II:
BD (n  27). Explosive brain death was defined as a
raumatic brain death that resulted from a gunshot wound
o the head (n  9), accidental head trauma (n  5), or a
learly definable intracranial bleed that progressed rapidly to
rain death (n  13). All others were classified as “non-
BD” cases. Adjudication of the mode of brain death was
erformed by an investigator blinded to all clinical and
ltrasound examination data. All transplant recipients stud-
ed provided informed consent, and the institutional review
oard approved the study.
ata collection. NONIMMUNOLOGICAL, METABOLIC, AND
NFECTION VARIABLES. Fasting lipid profile (triglyceride,
otal cholesterol, low-density lipoprotein-cholesterol, and
igh-density lipoprotein-cholesterol levels) at the time of
ltrasound examination, percentage weight gain post-
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March 3, 2004:806–10 Brain Death and Cardiac Allograft Vasculopathyransplant, hypertension (defined according to the Joint
ational Commission [JNC] VI criteria), diabetes mellitus,
onor age and gender, cold ischemic time, time since
ransplantation, and cytomegalovirus infection (defined as a
linical syndrome in association with either new serocon-
ersion, positive blood cultures, or evidence of tissue inva-
ion) requiring therapeutic intervention with intravenous
ancyclovir were assessed in all cardiac transplant recipients.
MMUNOLOGICAL RISK FACTORS. Rejection surveillance
uring the first year consisted of weekly endomyocardial
iopsies for the first month following transplantation, bi-
eekly until the third month, monthly until the sixth
onth, and bi-monthly thereafter until completion of the
rst year. Thus, the routine protocol mandates performance
f 13 to 14 biopsies during the first year. All biopsies were
raded on the basis of the standard biopsy-grading scheme
eveloped by the International Society for Heart and Lung
ransplantation (ISHLT). The criteria for treatment of
ellular rejection included the finding of a biopsy grade of
A or higher. If treatment was initiated for a lower biopsy
rade, it was done only in the presence of hemodynamic
ompromise as evidenced by one or more of the following:
20% decrease in the ventricular ejection fraction, increase
n the pulmonary capillary wedge pressure 25%, and a
ecrease by 25% in the cardiac index or an absolute value of
2.0 1/min/m2. Furthermore, episodes of treated rejection
andated the performance of a follow-up biopsy within one
o two weeks for documentation of resolution or regression
o a lower rejection grade.
Additionally, a first-year mean biopsy rejection score as
reviously described by us was determined for all patients
8). This was adapted from the standardized ISHLT crite-
ia, and individual scores were assigned to each defined
iopsy grade as follows: ISHLT grade 0  0; grade IA  1;
rade IB  2; grade 2  3; grade 3A  4; grade 3B  5;
nd grade 4  6. The mean biopsy score was computed as
he average of all biopsy scores during the first year
ollowing transplantation.
In addition, episodes of vascular (humoral) rejection and
he number of HLA-A, -B, or -DR matches between the
onor and recipient were assessed in all patients. Acute
ascular rejection was defined by the presence of hemody-
amic compromise along with histological evidence of
ndothelial cell activation and a positive immunofluores-
Abbreviations and Acronyms
CAD  coronary artery disease
CMV  cytomegalovirus
EBD  explosive brain death
HLA  human leukocyte antigen
ISHLT  International Society for Heart and Lung
Transplantation
JNC  Joint National Commissionence on biopsy. More importantly, we also assessed de- eailed immunosuppressant regimens in all patients and
alculated the cumulative prednisone dose (total amount of
V and oral prednisone consumed in grams [g]), average
aily prednisone dose (mg/kg/day), mean cyclosporine dose
mg/kg/day), and mean cyclosporine levels (pg/ml), as well
s mean azathioprine dose (mg/kg/day). Use of cytolytic
herapy (OKT3 or anti-thymocyte globulin) and use of
ethotrexate were also assessed for each study patient.
ntravascular ultrasound. CORONARY ULTRASOUND PRO-
EDURE. Coronary ultrasound was performed as we have
reviously reported (8). After administration of 200 g of
ntracoronary nitroglycerin, the ultrasound catheter was
ositioned in the distal segment of the target vessel over a
.014-inch (0.036-cm) guide wire. The target vessel was
elected by the presence of at least three easily definable and
eproducible branch points to assist in the accurate and
erial assessment of three regions of interest. The guide wire
as removed, and the ultrasound catheter was advanced to
he distal end of the ultrasound sheath under fluoroscopic
uidance. The drive module was then engaged, and contin-
ous images of the coronary artery were obtained as the
ltrasound transducer was slowly withdrawn. Additionally,
uoroscopic pictures and audio annotations were used to
nsure the correct localization of the artery segment for
ubsequent off-line analysis. Guiding catheter pressure,
T-segment changes, and cardiac rhythm were continu-
usly monitored during the procedure. After ultrasound
mages were obtained, both the transducer and sheath were
emoved, and a final angiogram was obtained to confirm the
atency of the coronary vessel. No complications were
ncountered except for coronary artery vasospasm readily
eversed by intracoronary infusion of nitrates or verapamil.
ORONARY ULTRASOUND ASSESSMENT. Intravascular ul-
rasound measurements were performed by one of the
nvestigators who had no knowledge of the prior assessment
f risk factors. Three coronary sites per vessel (proximal,
id, and distal), for a total of 183 coronary artery segments,
ere evaluated. The left anterior descending artery was
xamined in 54 patients, circumflex artery in 2, and right
oronary artery in the remaining 5 subjects. Maximal
ntimal thickness (measured as the mean of the maximal
hickness at the three sites evaluated) was obtained by
racing the lumen vessel wall interface and the external
order of the intimal layer. The definition of severe intimal
hickness was based upon the scheme previously described
y St. Goar et al. (9), wherein severe intimal thickening is
epresented by 0.5 mm of intimal proliferation involving
180° of the vessel circumference or any intimal layer 1.0
m in any one area of the vessel circumference. This
hreshold of severity denotes “unequivocal” presence of
ntimal thickening and is beyond the 98th percentile of any
ublished “normal” values. Moreover, we have previously
emonstrated that this threshold of severe intimal prolifer-
tion by intravascular ultrasound is predictive of cardiac
vents even in the absence of angiographic abnormalities,
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Brain Death and Cardiac Allograft Vasculopathy March 3, 2004:806–10nd therefore denotes a “prognostically relevant” threshold
f abnormality (10).
ardiac events. Cardiac events were defined as the occur-
ence of sudden cardiac death, myocardial infarction (MI),
nd need for coronary revascularization via percutaneous
echniques (angioplasty, atherectomy, stent implantation) or
urgical bypass.
tatistical methods. Normally distributed data are re-
orted as mean  SD. Differences between categorical
ariables were assessed using either the chi-square or the
isher exact test. An unpaired Student t test was used to
efine differences between continuous variables in sub-
roups. Kaplan-Meier actuarial analysis was used to assess
vent-free survival for the study cohort as a function of
ode of brain death. All analyses were performed using
tatview 4.5 (Abacus Concepts, Berkeley, California) sta-
istical software, and statistical significance was set at a p
alue 0.05.
ESULTS
linical characteristics. The study population included 61
onsecutive heart transplant recipients (49 men and 12
omen) with a mean age of 53  8 years (range: 21 to 69
ears) who were followed for an average of four years after
he index ultrasound (range of one to eight years of
ollow-up after index intravascular ultrasound). The index
ntravascular ultrasound was performed at an average of 2.4
ears’ posttransplantation (1 to 3.4 years’ posttransplanta-
ion). All subsequent data are presented between the two
roups identified as group I: non-EBD (n  34) or group
I: EBD (n  27).
ifferences in nonimmunological and infection variables.
able 1 lists comparative nonimmunological characteristics
f the non-EBD (group I) and EBD (group II) cohorts with
egard to recipient and donor age, recipient and donor
ender, cold ischemic time, lipid characteristics, weight
ain, cytomegalovirus (CMV) infection, and diabetes mel-
itus. Specifically, no significant clinical differences existed
etween the two groups with reference to any of these
onimmunological variables except for nonsignificant trends
able 1. Nonimmunological and Infectious Variables
Variable Non-EBD EBD p Value
ecipient age (yrs) 49  8 54  10 0.06
ecipient gender (men %) 80 80 NS
onor age (yrs) 25  9 29  13 NS
old ischemic time (min) 178  53 186  60 NS
osttransplant weight gain (%) 13  10 13  11 NS
otal cholesterol (mg/dl) 239  51 230  52 NS
DL cholesterol (mg/dl) 143  48 140  37 NS
ipid-lowering therapy (%) 30 30 NS
iabetes mellitus (%) 31 38 NS
MV infection (%) 16 26 0.09
MV  cytomegalovirus; EBD  explosive brain death; LDL  low-density
ipoprotein.f an older recipient age and more CMV infections in the wBD group. More importantly, no differences in donor and
ecipient CMV serological mismatches were noted.
ifferences in immunological variables. Table 2 lists a
omparison of immunological risk factors including episodes of
llograft rejection, numbers of human leukocyte antigen
HLA) matches, and mean first-year biopsy rejection score. No
ignificant differences were observed among clinical episodes of
llograft rejection, either cellular or humoral, hemodynamically
ompromising rejection, or number of HLA matches. Simi-
arly, no significant differences existed between the two groups
ith regard to average daily cyclosporine dose, mean azathio-
rine daily dose, as well as cumulative exposure to corticoste-
oids for the life of the allograft until the index intravascular
ltrasound. No significant differences existed between cytolytic
ntibody exposures between the two groups over the transplant
uration.
ntravascular ultrasound and survival analysis. Heart
ransplant recipients with allografts from EBD donors
emonstrated greater degrees of maximal intimal thickness
0.59  0.1 mm vs. 0.32  0.2 mm, p  0.02) and more
ardiac events (37 vs. 12%, p 0.01) in late follow-up when
ompared to those with non-EBD donors (cardiac events
escribed below) (Fig. 1). The predominant morphologic
haracteristics of the vessels studied revealed diffuse and
oncentric lesions (at least 2 or 3 segments) in 82%, whereas
nly 18% of vessels studied revealed proximal, focal, and
ccentric lesions. The intraobserver (4.1%) and interob-
erver (5.4%) variability was assessed as previously reported,
nd demonstrated good test reproducibility (8,10).
Ten cardiac events occurred in the EBD group (two
able 2. Immunological Variables
Variable
Non-EBD
(n  34)
EBD
(n  27) p Value
LA matches 0.8  0.9 1.1  1.3 NS
reated rejection (%) 18 19 NS
ean biopsy score 1  0.3 1  0.3 NS
ean cyclosporine dose (mg/kg/day) 4  1.5 3.9  1.8 NS
ean azathioprine dose (mg/kg/day) 1.3  0.6 1.4  0.5 NS
umulative prednisone dose (g) 9.7  4.4 8.8  4.4 NS
LA  human leukocyte antigen. Other abbreviations as in Table 1.
igure 1. Severity of intimal thickening by intravascular ultrasound among
ardiac allograft recipients with donors who suffered nonexplosive brain
eath compared to those with explosive brain death. The explosive brain
eath donor hearts developed significantly greater intimal thickening,
hich crossed the prognostically relevant threshold of 0.5 mm.
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March 3, 2004:806–10 Brain Death and Cardiac Allograft Vasculopathyercutaneous coronary interventions, three MIs, three sud-
en deaths, and two deaths due to allograft failure). The
on-EBD group suffered four events (one percutaneous
oronary intervention, one sudden death, and two deaths
elated to late allograft failure). Allografts from EBD
onors demonstrated lower survival (63  19 months vs. 72
17 months) compared with non-EBD donors (p 0.04).
ctuarial survival analysis confirmed the significant predic-
ive impact of EBD and severe intimal thickening on
ardiac events (log rank, p  0.01) (Fig. 2).
In a multivariate model, EBD (r  0.28; p  0.02)
ersisted as an independent predictor of intimal thickness in
oncert with donor age (r  0.42; p  0.008) and lower
verage daily cyclosporine dose (r  0.25; p  0.05).
ISCUSSION
tudy findings. The principal findings of this investigation
emonstrate that cardiac allograft vasculopathy is influenced by
onor events that precede the actual engraftment process.
ndeed, the notion that allograft vasculopathy is predominantly
etermined by immunological interactions is definitively chal-
enged by these observations, which suggest that “pre-
ngraftment” factors such as the mode of brain death likely lay
he groundwork for the later development of cardiac allograft
asculopathy. Furthermore, this investigation points out that
ot only is the mode of donor brain death associated with an
ncrease in the development of severe intimal proliferation but
lso that this finding is predictive of adverse late clinical
utcome from cardiac events.
arly events and cardiac allograft vasculopathy. The
ecognition that rejection-independent events could influ-
nce the development of cardiac allograft vasculopathy
ecame obvious by investigations that pointed to the role of
schemia-reperfusion injury surrounding engraftment, the
ontribution of advanced donor age, and aberrations within
he microvasculature, including such metabolic derange-
ents as hyperlipidemia (6–8,11). Several important inves-
igations have linked microvascular fibrin, depletion of
igure 2. Actuarial survival curve depicting freedom from cardiac events
uring late follow-up demonstrating the adverse impact of explosive brain
eath on survival compared to non-explosive brain death.rteriolar tissue plasminogen activator factor, and even systemic inflammation, all rejection-independent events, as
ignificant correlates of the future risk for cardiac allograft
asculopathy and allograft loss (6,7,12). Does the process of
rain death and its severity play an integral role in deter-
ining these early allograft findings that influence the
evelopment of cardiac allograft vasculopathy?
rain death and coronary effects. The contribution of
rain death to the eventual development of cardiac allograft
asculopathy was pointed out recently by Anyanwu et al.
13), who studied the incidence and severity of transplant-
ssociated coronary artery disease (CAD) in recipients of
omino hearts (living-related heart transplantation from
ecipients who require heart-lung transplantation). These
nvestigators suggested that such allograft recipients suffered
ess development of angiographic CAD compared to cadav-
ric heart transplantation. It has been demonstrated that
apid brain death induces a calcium overflow injury that
ffects conduction tissue, coronary artery smooth muscle,
nd myocardial cells (14). Others have shown that the event
f EBD is associated with a generalized activation of
acrophage-associated cytokines in all peripheral organs
ncluding the heart. An investigation by Takada et al. (15)
lso demonstrated an up-regulation of immunoregulatory
nd adhesion cell molecules, arguing that the event of brain
eath sets up the allograft for adverse donor-host interac-
ions following engraftment. More recently, Segel and
olleagues (2) evaluated the impact of brain death on
easures of endothelial dysfunction and showed the up-
egulation of adhesion cell molecules and pro-inflammatory
ytokines, suggesting a state of endothelial inflammation in
rain death even if the circulation remains perceptibly
table. Szabo et al. (16,17) have demonstrated similar events
n a canine model of brain death wherein they found that
rain death affects coronary circulation by impairment of
oronary blood flow and by the induction of severe endo-
helial dysfunction.
ode of brain death and outcomes. It has been known
hat the severity of brain death is related to hemodynamic
nstability in the donor and can be reversible. Thus, it is
nlikely that permanent myocardial injury is a conclusive
vent, and Szabo et al. (16,17) have suggested that the
emodynamic instability likely reflects altered loading con-
itions and impaired coronary perfusion than neurohor-
onally mediated myocardial injury. A provocative investi-
ation by Birks et al. (18) demonstrated an elevation in
ro-apoptotic capsases in dysfunctional donor hearts, which
hey linked to inflammatory activation, thereby alluding to a
otential cellular mechanism of subclinical cardiac
athology.
omparison with other published studies. Clinical con-
rmation of these pathological observations has only been
parsely forthcoming. Tsai et al. (19) hypothesized that
traumatic intracranial bleeds, typically associated with
lder donors, might be associated with increased risk of
raft failure in heart transplantation. These investigators
uggested that an intracranial bleed might represent an
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Brain Death and Cardiac Allograft Vasculopathy March 3, 2004:806–10ndependent risk for poor long-term outcomes; furthermore,
hey demonstrated that such donor allografts have a higher risk
or development of angiographic CAD than those without.
ore recently, Yamani et al. (20) examined the risk of CAD
n relation to the presence of spontaneous intracranial bleeds in
he donor. These researchers found a lower freedom from
AD at five years coupled with worse survival in such
ndividuals. Our investigation further amplifies these data
ecause we have been able to demonstrate that it is an explosive
ode of brain death that likely arbitrates this adverse outcome
ather than a specific attribute confined to intracranial bleed-
ng. Of note, the degree of intimal proliferation observed by
ntravascular ultrasound crossed the threshold of prognostically
elevant intimal thickening, as in previous studies (4,5,8).
urthermore, our data establishes the independent impact of
ode of EBD on late outcomes from cardiac allograft vascu-
opathy, independent of other clinical variables, since most
mmunological and nonimmunological variables were similarly
pread across the two groups evaluated. Interestingly, our data
nce again, as in the past, confirmed the importance of not
nly older donor age but also lower exposure to calcineurin
nhibitors as other important factors in determining late
rognosis from cardiac allograft vasculopathy (21).
tudy limitations. Our investigation enrolled those pa-
ients who underwent a one-year intravascular study result-
ng in an exclusion of early deaths. This culminated in an
xclusion of six patients (allowing only 61 evaluable pa-
ients) who were unable to achieve survival to intravascular
ltrasound. Interestingly, four of these six patients were
lassified as allografts from donors with an EBD. Thus,
nclusion of these patients would only have strengthened the
dverse prognostic implication of mode of brain death.
nother potential limitation pertains to the low use of
ipid-lowering therapy in our two groups, but this reflects
he time of patient recruitment when the value of lipid-
owering therapy in heart transplantation was just emerging.
onclusions. Finally, this investigation suggests that explo-
ive mode of brain death, a pre-engraftment factor, is a
ignificant determinant for the late development of cardiac
llograft vasculopathy and adversely influences long-term allo-
raft survival. Thus, strategies that focus on limitation of
ascular allograft injury in the pre-engraftment phase of cardiac
ransplantation are warranted and should be developed.
eprint requests and correspondence: Dr. Mandeep R. Mehra,
ardiomyopathy and Heart Transplantation Center, Ochsner
linic Foundation, 1514 Jefferson Highway, New Orleans, Lou-
siana 70121. E-mail: mmehra@ochsner.org.
EFERENCES
1. Novitzky D, Rhodin J, Cooper DK, Ye Y, Min KW, DeBault L.
Ultrastructure changes associated with brain death in the human donor
heart. Transpl Int 1997;10:24–32.2. Segel LD, vonHaag DW, Zhang J, Follette DM. Selective overex-
pression of inflammatory molecules in hearts from brain-dead rats.
J Heart Lung Transplant 2002;21:804–11.
3. Shivalkar B, Van Loon J, Wieland W, et al. Variable effects of
explosive or non-explosive increase of intracranial pressure on myo-
cardial structure and function. Circulation 1993;87:230–9.
4. Mehra MR. Crossing the vasculopathy bridge from morphology to
therapy: a single center experience. J Heart Lung Transplant 2000;19:
522–8.
5. Rickenbacher PR, Pinto FJ, Lewis NP, et al. Prognostic importance of
intimal thickness as measured by intracoronary ultrasound after cardiac
transplantation. Circulation 1995;92:3445–52.
6. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular tissue
plasminogen activator and the development of coronary artery disease
in heart-transplant recipients. N Engl J Med 1995;333:1111–6.
7. Labarrere CA, Nelson DR, Cox CJ, et al. Cardiac-specific troponin I
levels and risk of coronary artery disease and graft failure following
heart transplantation. JAMA 2000;284:457–64.
8. Mehra MR, Ventura HO, Chambers R, et al. Predictive model to
assess risk for cardiac allograft vasculopathy: an intravascular ultra-
sound study. J Am Coll Cardiol 1995;26:1537–44.
9. St. Goar FG, Pinto FJ, Alderman EL, et al. Intracoronary ultrasound
in cardiac transplant recipients. In vivo evidence of “angiographically
silent” intimal thickening. Circulation 1992;85:979–87.
0. Mehra MR, Ventura HO, Stapleton DD, et al. Presence of severe
intimal thickening by intravascular ultrasonography predicts cardiac
events in cardiac allograft vasculopathy. J Heart Lung Transplant
1995;14:632–9.
1. Yamani MH, Tuzcu EM, Starling RC, et al. Myocardial ischemic
injury after heart transplantation is associated with upregulation of
vitronectin receptor (alpha (v) beta3), activation of the matrix metal-
loproteinase induction system, and subsequent development of coro-
nary vasculopathy. Circulation 2002;105:1955–61.
2. Pethig K, Heublein B, Kutschka, Haverich A. Systemic inflammatory
response in cardiac allograft vasculopathy: high sensitivity C-reactive
protein is associated with progressive luminal obstruction. Circulation
2000;102 Suppl III:233–6.
3. Anyanwu AC, Banner NR, Mitchell AG, Khaghani A, Yacoub MH.
Low incidence and severity of transplant-associated coronary artery
disease in heart transplants from live donors. J Heart Lung Transplant
2003;22:281–6.
4. Novitzky D, Rose AG, Cooper DK. Injury of myocardial conduction
tissue and coronary artery smooth muscle following brain death in the
baboon. Transplantation 1988;45:964–6.
5. Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive
brain death on cytokine activation of peripheral organs in the rat.
Transplantation 1998;65:1533–42.
6. Szabo G, Hackert T, Buhmann V, Sebening C, Vahl CF, Hagl S.
Myocardial performance after brain death: studies in isolated hearts.
Ann Transplant 2000;5:45–50.
7. Szabo G, Buhmann V, Bahrle S, Vahl CF, Hagl S. Brain death
impairs coronary endothelial function. Transplantation 2002;73:
1846–8.
8. Birks EJ, Yacoub MH, Burton PS, et al. Activation of apoptotic and
inflammatory pathways in dysfunctional donor hearts. Transplantation
2000;70:1498–506.
9. Tsai FC, Marelli D, Bresson J, et al. UCLA Heart Transplant Group.
Use of hearts transplanted from donors with atraumatic intracranial
bleeds. J Heart Lung Transplant 2002;21:623–8.
0. Yamani MH, Starling RC, Tuzcu EM, et al. Donor intracranial
bleeding is associated with advanced transplant coronary vasculopathy:
evidence from intravascular ultrasound (abstr). J Heart Lung Trans-
plant 2003;22:S76.
1. Mehra MR, Ventura HO, Chambers RB, Ramireddy K, Smart FW,
Stapleton DD. The prognostic impact of immunosuppression and
cellular rejection on cardiac allograft vasculopathy: time for a reap-
praisal. J Heart Lung Transplant 1997;16:743–51.
